Testing the amount of nicotinamide mononucleotide and urolithin A as compared to the label claim.
Level 5 - mechanism / opinion, no new human data
Bench analytical product-testing study without human participants (graded by design analogy)
PubMed 38935229 · doi:10.1007/s11357-024-01257-2
What was done
Nicotinamide mononucleotide (NMN) and urolithin A dietary supplements purchased online or in pharmacies were tested to measure their active ingredient content relative to the amounts stated on their labels.
What was found
Active ingredient content deviated significantly from label claims, ranging from +28.6% to -100%. No other numbers or sample sizes are reported in the abstract.
Why it matters
Demonstrates substantial quality control variability and the risk of completely inactive products among commercially available longevity supplements due to limited regulatory oversight.
Limits
The abstract does not disclose the sample size, specific analytical methods, brands tested, or lot-to-lot variability. No human biological or clinical outcomes were evaluated.
Cited by
- supports A study by a researcher in Singapore found that many of 10 tested commercial preparations of NMN did not contain what was on their labels.